Emergent Biosolutions ( (EBS) ) has shared an update.
On March 10, 2025, Emergent BioSolutions announced the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million. The agreement allows Emergent to retain rights to manufacturing services at the facility for future growth and pandemic response. This transaction is part of Emergent’s multi-year transformation plan to streamline operations and enhance its manufacturing network, which includes facilities in Lansing, Michigan, and Winnipeg, Canada. The sale is expected to close in the first quarter of 2025, following customary closing conditions.
More about Emergent Biosolutions
Emergent BioSolutions Inc. is a company focused on delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies. With over 25 years of experience, Emergent is committed to preparing communities around the world for current and future health challenges.
YTD Price Performance: -43.82%
Average Trading Volume: 1,172,226
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $313.5M
For a thorough assessment of EBS stock, go to TipRanks’ Stock Analysis page.